Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07046975 · ClinicalTrials.gov registry record · Phase 3
Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone
A Phase 3 study, sponsored by Sarfez Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT07046975 is a Phase 3 study that has completed, run by Sarfez Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT07046975, a Phase 3 study, has completed, sponsored by Sarfez Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
Interventions
- DRUG Torsemide and Spironolactone tablet
- DRUG Torsemide Tablets and Spironolactone Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-06-15 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07046975
The ClinicalTrials.gov registry entry for NCT07046975 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarfez Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Torsemide and Spironolactone tablet is the first listed.
NCT07046975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07046975 about?
NCT07046975 is a clinical study titled "Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone". To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
What is the current status of trial NCT07046975?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2025-06-15. Estimated completion is 2026-02-28.
What interventions are being tested in trial NCT07046975?
The interventions under investigation include: Torsemide and Spironolactone tablet (DRUG), Torsemide Tablets and Spironolactone Tablets (DRUG).
Who is sponsoring clinical trial NCT07046975?
This trial is sponsored by Sarfez Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.